FDA hands Biovail a non-approval letter

The FDA has slapped Canada-based Biovail with a Non-Approval letter for BVF-033, a once-daily salt formulation of bupropion. The FDA said the design of the pharmacokinetic studies required to support the NDA was not sufficient. The company said that though it believes the studies were adequate, it will meet with the agency to resolve the problem.

- see the release for more

PLUS: Funding remains crucial for Canada's biotech industry. Release

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.